174 related articles for article (PubMed ID: 23225807)
1. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Kim G; Jung EJ; Ryu CG; Hwang DY
Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
[TBL] [Abstract][Full Text] [Related]
2. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
Hanke B; Riedel C; Lampert S; Happich K; Martus P; Parsch H; Himmler B; Hohenberger W; Hahn EG; Wein A
Ann Oncol; 2001 Feb; 12(2):221-6. PubMed ID: 11300328
[TBL] [Abstract][Full Text] [Related]
3. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G
Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
[TBL] [Abstract][Full Text] [Related]
5. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
[TBL] [Abstract][Full Text] [Related]
6. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
[TBL] [Abstract][Full Text] [Related]
7. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
Nagai Y; Beppu T; Sakamoto Y; Miyamoto Y; Hayashi H; Nitta H; Imai K; Masuda T; Okabe H; Hirashima K; Imamura Y; Baba Y; Chikamoto A; Baba H
Anticancer Res; 2014 Oct; 34(10):5529-35. PubMed ID: 25275051
[TBL] [Abstract][Full Text] [Related]
8. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
10. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
11. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Fan FS; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Int J Colorectal Dis; 2001 Apr; 16(2):96-101. PubMed ID: 11355325
[TBL] [Abstract][Full Text] [Related]
13. Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancers.
Ychou M; Duffour J; Kramar A; Grenier J
Oncol Rep; 1998; 5(5):1245-50. PubMed ID: 9683844
[TBL] [Abstract][Full Text] [Related]
14. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Nozawa H; Ishihara S; Kawai K; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Watanabe T
Oncology; 2016; 91(3):127-34. PubMed ID: 27362767
[TBL] [Abstract][Full Text] [Related]
16. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
Trillet-Lenoir V; Chapuis F; Touzet S; Barbier JY; Freyer G; Gaudin JL; Lombard-Bohas C; Valette PJ; Lledo G; Gouttebel MC; Boyer JD; Chassignol L; Hamon H; Claudel-Bonvoisin S; Leprince E; Amoyal P; Glehen O; Darnand P; Heilmann MO; Bleuse JP
Clin Oncol (R Coll Radiol); 2004 May; 16(3):196-203. PubMed ID: 15191007
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy.
Mao J; Du P; Yang HT; Hu H; Wang SY; Wu X; Cheng ZB
Medicine (Baltimore); 2020 Apr; 99(14):e19420. PubMed ID: 32243362
[TBL] [Abstract][Full Text] [Related]
18. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
Marks EI; Brennan M; El-Deiry WS
Cancer Biol Ther; 2015; 16(8):1136-9. PubMed ID: 26047368
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
Iwanicki-Caron I; Di Fiore F; Roque I; Astruc E; Stetiu M; Duclos A; Tougeron D; Saillard S; Thureau S; Benichou J; Paillot B; Basuyau JP; Michel P
J Clin Oncol; 2008 Aug; 26(22):3681-6. PubMed ID: 18669452
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
